Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA public affairs

Executive Summary

Consultant Alixe Mattingly is returning to the Pharmaceutical Research & Manufacturers of America as acting VP-public affairs while the association completes its search for a successor to Chris Molineaux (1"The Pink Sheet" June 24, p. 36). Mattingly will split time between PhRMA headquarters and Santa Barbara, Calif. She previously served as PhRMA's head of public affairs before relocating to California (2"The Pink Sheet" Feb. 7, 2000, p. 7)...

You may also be interested in...



PhRMA’s Badge Of Merritt: AAHP Exec Joining Rx Association As Head Of PR

American Association of Health Plans Senior VP Mark Merritt is joining the Pharmaceutical Research & Manufacturers of America to head the trade association's public relations effort effective Oct. 7

PhRMA Searching For New VP-Public Relations; Molineaux To Leave In Sept.

The Pharmaceutical Research & Manufacturers of America is looking for a new head of public relations heading into the November elections

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel